Deprez et al., “Sulfonylureas and Sulfonylcarbamates as New Non-Tetrazole Angiotensin II Receptor Antagonists, Discovery of a Highly Potent Orally Active (Imidazolylbiphenylyl)sulfonylurea (HR 720),” J. Med. Chem., 38:2357-2377 (1995). |
Ashton et al., “Triazolinone Biphenylsulfonamide Derivatives as Orally Active Angiotensin II Antagonists with Potent AT, Receptor Affinity and Enchanched AT2 Affinity 1,2,” J. Med. Chem., 37:2808-2824 (1994). |
Matsumura et al. “Studies of Nitriles. XI. Preparation and Chemistry of Schiff Bases of ADAN, 2-Amino-3,3-dichloroacrylonitrile. A highly Effective Conversion into 2-Substituted-4(5)-chloroimidazole-5(4)-carbaldehydes,” Chem. Pharm. Bull. 24(5):960-969 (1976). |
Almansa et al., “Synthesis and Structure—Activity Relationship of a New Series of Potent AT, Selective Angiotensin II Receptor Antagonists: 5-(Biphenyl-4-ylmethyl)pyrozoles,” J. Med. Chem. 40:547-558 (1997). |
Derwent Abstract of EP 0648763, 1994. |
Faber et al., “A Novel Screening Assay of the Na+-Dependent CI-/HCO3-Exchanger (NCBE) and its Inhibitors”, Cell Physiol. Biochem., 6:39-49 (1996). |
Fernandez et al., “Angiotensin AT(2) Receptor Stimulation Increases Survival in Gerbils with Abrupt Unilateral Carotid Ligation,” J. Cardiovasc. Pharmacol., vol. 124, No. 6, 1994, pp. 937-940. |
Liu et al., “Paracrine Systems in the Cardioprotective Effect of Angiotensin-Converting Enzyme Inhibitors on Myocardial Ischemia/Reperfusion Injury in Rats,” Hypertension, vol. 27, No. 1, 1996, pp. 7-13. |
Thomas et al., “Losartan Exerts Antiarrhythmic Activity Independent of Angiotensin II Receptor Blockade in Simulated Ventricular Ischemia and Reperfusion,” J. Pharmacol. Exp. Ther., vol. 278, No. 3, 1996, pp. 1090-1097. |
Hartman et al., “Reduction of Myocardial Infarct Size by Ramiprilat is Independent of Angiotensin II Synthesis Inhibition,” Eur. J. Pharmacol., vol. 234, No. 2-3, 1993, pp. 229-236. |
Koke et al., “The Cardiac Renin-Angiotensin System and Myocardial Stunning in the Dog Heart,” Biomed. Lett., vol. 48, No. 190, 1993, pp. 97-113. |
Ford et al., “Opposite Effects of Angiotensin AT(1) and AT(2) Receptor Antagonists on Recovery of Mechanical Function After Ischemia-Reperfusion in Isolated Working Rat Hearts,” Circulation, vol. 94, No. 12, 1996, pp. 3087-3089. |
Heller et al., “Losartan Protects the Rat Kidney from Ischemic Injury,” Kidney Int., vol. 49, No. Suppl. 55, 1996, pp. S113-S114. |
Werrmann et al., “Use of Losartan to Examine the role of the Cardiac Renin-Angiotensin System in Myocardial Dysfunction During Ischemia and Reperfusion,” J. Cardiovasc. Pharmacol., vol. 27, No. 2, 1996, pp. 177-182. |
Patent Abstracts of Japan, vol. 018, No. 236, May 6, 1994 & JP 06 025229 A (Japan Tobacco Inc.), Feb. 1, 1994. |
Patent Abstracts of Japan, vol. 012, No. 353, Sep. 21, 1988, & JP 63 107963 A (Toyama Chem. Co., Ltd.), May 12 1988. |
Copy of co-pending patent application No. 09/010,181, filed on Jan. 21, 1998. |